Table 1.
Characteristics of patients with locoregional advanced NPC assessed in this study
| Characteristic | PET/CT-guided DP-IMRT | CT-based IMRT | p value* |
|---|---|---|---|
| No. of patients (%) | No. of patients (%) | ||
| Total | 101 | 112 | |
| Age, y | |||
| Median | 46 | 47 | |
| Range | 22–70 | 18–67 | |
| Sex | |||
| Male | 66 (65.3) | 78 (69.6) | 0.464 |
| Female | 35 (34.7) | 33 (29.5) | |
| Pathology | |||
| WHO type 2 | 30 (29.7) | 37 (33.0) | 0.659 |
| WHO type 3 | 71 (70.3) | 75 (67.0) | |
| T stage | |||
| T1 | 10 (9.9) | 13 (11.6) | 0.955 |
| T2 | 27 (26.7) | 30 (26.8) | |
| T3 | 30 (29.7) | 30 (26.8) | |
| T4 | 34 (33.7) | 39 (34.8) | |
| N stage | |||
| N0 | 3 (3) | 3 (2.7) | 0.654 |
| N1 | 10 (9.9) | 6 (5.4) | |
| N2 | 67 (66.3) | 79 (70.5) | |
| N3 | 21 (20.8) | 24 (21.4) | |
| AJCC stage group | |||
| III | 49 (48.5) | 59 (52.7) | 0.790 |
| IVA | 32 (31.7) | 31 (30.7) | |
| IVB | 20 (19.8) | 22 (19.8) | |
| EBV DNA | |||
| ≥ 4000 copies/ml | 49 (48.5) | 46 (40.7) | 0.334 |
| < 4000 copies/ml | 52 (51.5) | 66 (59.3) | |
| Concurrent chemotherapy | |||
| Yes | 99 (98.0) | 110 (98.2) | 0.649 |
| No | 2 (2) | 2 (1.8) | |
| Induction chemotherapy | |||
| Yes | 26 (25.7) | 30 (26.8) | 0.875 |
| No | 75 (74.3) | 82 (73.2) | |
| Adjuvant chemotherapy | |||
| Yes | 8 (7.9) | 12 (10.7) | 0.490 |
| No | 93 (92.1) | 98 (89.3) | |
*p values were calculated by the χ 2 test